These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38840237)

  • 21. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
    Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1.
    Kijima T; Koga F; Fujii Y; Yoshida S; Tatokoro M; Kihara K
    PLoS One; 2013; 8(5):e64615. PubMed ID: 23741352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
    Roulin D; Waselle L; Dormond-Meuwly A; Dufour M; Demartines N; Dormond O
    Mol Cancer; 2011 Jul; 10():90. PubMed ID: 21791089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway.
    Sim MY; Yuen JSP; Go ML
    Sci Rep; 2018 Jul; 8(1):10289. PubMed ID: 29980758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance.
    Lei Y; Geng Z; Guo-Jun W; He W; Jian-Lin Y
    Mol Cell Biochem; 2010 Nov; 344(1-2):23-31. PubMed ID: 20563741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK; Quinn DI
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
    Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
    Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unconventional mechanism of action and resistance to rapalogs in renal cancer.
    Yang J; Butti R; Cohn S; Toffessi-Tcheuyap V; Mal A; Nguyen M; Stevens C; Christie A; Mishra A; Ma Y; Kim J; Abraham R; Kapur P; Hammer RE; Brugarolas J
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2310793121. PubMed ID: 38861592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma.
    Yangyun W; Guowei S; Shufen S; Jie Y; Rui Y; Yu R
    Gene; 2022 Jan; 809():145992. PubMed ID: 34648917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer.
    Kiyohara Y; Yoshino K; Kubota S; Okuyama H; Endo H; Ueda Y; Kimura T; Kimura T; Kamiura S; Inoue M
    Cancer Sci; 2016 Apr; 107(4):452-60. PubMed ID: 26825848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.
    Mukherjee B; Tomimatsu N; Amancherla K; Camacho CV; Pichamoorthy N; Burma S
    Neoplasia; 2012 Jan; 14(1):34-43. PubMed ID: 22355272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A
    Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
    Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
    Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
    Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
    Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
    Lv P; Wang Y; Ma J; Wang Z; Li JL; Hong CS; Zhuang Z; Zeng YX
    Oncotarget; 2014 Sep; 5(17):7512-24. PubMed ID: 25245035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
    Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
    Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
    Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
    Elfiky AA; Aziz SA; Conrad PJ; Siddiqui S; Hackl W; Maira M; Robert CL; Kluger HM
    J Transl Med; 2011 Aug; 9():133. PubMed ID: 21834980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.